Kummerfeld Keith C 4

4 · Arcturus Therapeutics Holdings Inc. · Filed Jul 18, 2023

Form 4

Period: 2023-07-14

See Remarks

Transactions

Exercise/Conversion
Employee Stock Option (right to buy)
2023-07-14−1,031→ 7,938 total
Exercise: $14.12Exp: 2030-02-18→ Common Stock (1,031 underlying)
Exercise/Conversion
Common Stock
2023-07-14$9.04/sh+4,500$40,680→ 5,450 total
Exercise/Conversion
Common Stock
2023-07-14$4.99/sh+1,437$7,171→ 6,887 total
Sale
Common Stock
2023-07-14$35.00/sh−6,968$243,880→ 950 total
Exercise/Conversion
Employee Stock Option (right to buy)
2023-07-14−4,500→ 21,000 total
Exercise: $9.04Exp: 2028-07-04→ Common Stock (4,500 underlying)
Exercise/Conversion
Common Stock
2023-07-14$14.12/sh+1,031$14,558→ 7,918 total
Exercise/Conversion
Employee Stock Option (right to buy)
2023-07-14−1,437→ 7,126 total
Exercise: $4.99Exp: 2029-02-06→ Common Stock (1,437 underlying)

Footnotes (3)

[F1]Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
[F2]These shares were sold in multiple transactions, each at a price of $35.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it on July 14, 2023.
[F3]25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

Documents

1 file